Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-02-17
2000-07-04
Davis, Zinna Northington
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546329, A61K 3144, C07D21170
Patent
active
060839643
ABSTRACT:
A specific method of optical resolution using dibenzoyltartrate (DBTA) is described for the preparation of six new (+) and (-) enantiomers each of six racemic aminoalkylpyridines. The (+) enantiomers are potent orally active, non-neurotoxic anticonvulsant compounds that are highly effective in the MES test and the hippocampal kindled rat model with no activity in the sc Met test and that significantly raise seizure threshold in the i.v. Metrazol seizure threshold screen. Pharmaceutical compositions, to treat convulsive disorders, comprising as the active ingredient one of the above (+) or (-) aminoalkylpyridine enantiomers, that are selected from the groups of enantiomers consisting of those of the formulae: ##STR1## wherein R.sup.1 is methyl or ethyl and R.sup.2 is 3,4-dichloro, p- or m-chloro or p-bromo. The compositions are administered to mammals in an amount to provide a dosage amount ranging from about 10 mg/kg to 200 mg/kg of body weight.
REFERENCES:
patent: 4511572 (1985-04-01), Kadaba
patent: 4610994 (1986-09-01), Kadaba
patent: 4618681 (1986-10-01), Kadaba
patent: 4689334 (1987-08-01), Kadaba
patent: 4820721 (1989-04-01), Kadaba
patent: 5206254 (1993-04-01), Gandolfi et al.
patent: 5648369 (1997-07-01), Kadaba et al.
Williams et al.--Importance of Drug Enantiomers in Clinical Pharmacology--Drgs 30: 333-354 (1985).
Kadaba, et al.--Triazolines--XXVII..DELTA..sup.2 -1,2,3-Triazoline Anticonvulsants: Novel `Built-in` Heterocyclic Prodrugs with a Unique `Dual-Action` Mechanism for Imparing Excitatory Amino Acid L-Glutamate Neurotransmission.sup.1, Bioorganic & Medicinal Chemistry, vol. 4, No.2, pp 165-178, 1996.
James McNamara et al.--The Kindling Model of Epilepsy: A Review, Progress in Neurobiology, vol. 15, pp 139 to 159 (1980).
John Caldwell et al.--The pharmacological and toxicological significance of the sterochemistry of drug disposition, Xenobiotica, 1988, vol. 18, Supp. No. 1, 59-70.
Deshmukh et atl.--Identification of the Triazoline Pharmacophore and the Evolution of the Aminoalkylpyridines. A new class of Potent Orally Active Anticonvulsant Agents, Medicinal Chemistry Research, 1993, vol. 3 pp. 223-232.
Ariens--Nonchiral, homochiral and composite chiral drugs--1993, Elsevier Science Publishers, Ltd.
Simonyi--On Chiral Drug Action--The Central Research Institute for Chemistry, Hungarian Academy of Sciences, pp 359-413 (1993).
Porter--Mechanisms of Action of New Antiepileptic Drugs, Epilepsia 30(Suppl 1):S29-S34, 1989.
Foster, et al.--Acidic Amino Acid Binding Sites in Mammalian Neuronal Membranes: Their characteristics and Relationship to Synaptic Receptors, Brain Researh Reviews, 7 (1984) 103-164.
Watkins--Excitatory Amino Acid Transmitter--Ann. Rev. Pharmacol. Toxicol, 1981, 21:165-204.
Racine--Kindling: The First Decade--Neurosurgery, vol. 3, No. 2, 1978, pp. 234-252.
Schwarcz, et al.-Excitatory Amino Acids and Epilepsy, Plenum Press, New York, 1986.
Watkins et al.--Excitatory Amino Acid Transmitters, Annual Reviews in Pharmacology & Toxicology, 1982, vol. 21, pp 165-204.
Porter et al.--Antiepileptic Drug Development Program, Cleveland Clinic Quarterly, vol. 51, No. 2, 1984, pp. 293-305.
Porter et al.--Antiepileptic Drugs--In Basic and Clinical Pharmacology 4th Edn., pp. 287-303.
Stinson--Chiral Drug Market Shows Signs of Maturity, Chemical and Engineering News, Oct. 20, 1997, pp. 38-70.
Stinson--Chiral Drugs, Chemical & Engineering News, Sep. 27, pp. 38-65-1993.
Stinson--Counting on Chiral Drugs, Chemical and Engineering News, Sep. 21, 1998, pp. 83-104.
Davis Zinna Northington
K and K Biosciences, Inc.
Robinson Binta
LandOfFree
Optical resolution of racemic aminoalkylpyridine anticonvulsants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Optical resolution of racemic aminoalkylpyridine anticonvulsants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Optical resolution of racemic aminoalkylpyridine anticonvulsants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1486913